As the GFR loss aggravates, the disturbed mineral metabolism worsens the bone
microstructure and remodelling‐scenario, which is known as CKD‐mineral bone disease …

In the course of chronic kidney disease (CKD), alterations in the bone-vascular axis
augment the risk of bone loss, fractures, vascular and soft tissue calcification, left ventricular …

Objective In this study, we aimed to establish the causal effects of lowering sclerostin, target
of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors. Methods …

Fibroblast Growth Factor 23 (FGF23) and Klotho play an essential role in the regulation of
mineral metabolism, and both are altered as a consequence of renal failure. FGF23 …

The WNT signalling pathway is a key regulator of bone metabolism, particularly bone
formation, which has helped to define the role of osteocytes—the most abundant bone cells …

Background Disordered mineral and bone metabolism is a common complication of chronic
kidney disease (CKD). Bone biopsy remains the gold standard tool for evaluating renal …

The chronic kidney disease-mineral bone disorder (CKD-MBD) is a complex multi-
component syndrome occurring during kidney disease and its progression. Here, we update …

Sclerostin is a Wnt signaling pathway inhibitor that negatively regulates bone formation.
Bone-marrow-derived stromal cell (BMSC) differentiation is influenced by the Wnt pathway …

The causes of the increased cardiovascular risk associated with kidney diseases partly
reside in the chronic kidney disease–mineral bone disorder (CKD–MBD) syndrome. Three …

Unmet needs challenge clinical management of sepsis especially concerning patient
profiling, enhancing recovery, and long-term sequelae. Here, we preliminarily focused on …